FDA accepts supplemental NDA for WIDAPLIK by AZURITY
The FDA has accepted the supplemental NDA for WIDAPLIK (NDA219423) submitted by AZURITY, with a standard review priority.
Asset / Drug
Drug and asset intelligence for AZURITY with 14 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.